Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature Medicine

Topics

Physics

Immunology

Medicine

Internal Medicine

Infectious Diseases

Show all topics

DOI

10.1038/s41591-020-01179-4

License

other-oa